olokizumab (103)

Structure	 

Heavy chain / Chaone lourde / Cadena pesada

EVQLVESGGG LVQPGGSLRL SCAASGFNFN DYFMNWVRQA PGKGLEWVAQ  50

MRNKNYQYGT YYAESLEGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR 100

ESYYGFTSYW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150

DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200

YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250

LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300

RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350

LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400

DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK    447

Light chain / Chaone lygire / Cadena ligera

DIQMTQSPSS LSASVGDRVT ITCQASQDIG ISLSWYQQKP GKAPKLLIYN  50

ANNLADGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCLQ HNSAPYTFGQ 100

GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150

DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200

LSSPVTKSFN RGEC                                        214

Disulfide bridges location / Position des ponts disulfure / Posiciones
de los puentes disulfuro

Intra-H	22-98	147-203	261-321	367-425

	22??-98??	147??-203??	261??-321??	367??-425??

Intra-L	23?-88?	134?-194?



	23???-88???	134???-194???



Inter-H-L	134-214?	134??-214???



Inter-H-H	226-226??	229-229??





N-glycosylation sites / Sites de N-glycosylation / Posiciones de
N-glicosilaciun

297, 297??

CAS		1007223-17-7

Description

immunoglobulin G4-kappa, anti-[Homo sapiens IL6 (interleukin 6; IL-6)],
humanized monoclonal antibody;

gamma4 heavy chain (1-447) [humanized VH (Homo sapiens IGHV3-72*01
(84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo sapiens IGHG4*01
hinge S10(228)>P (121-447)], (134-214?)-disulfide with kappa light chain
(1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01 (84.20%)
-IGKJ2*01) [6.3.9] (1?-107?) -Homo sapiens IGKC*01 (108?-214?)];
(226-226":229-229")-bisdisulfide dimer 

immunoglobuline G4-kappa, anti-[Homo sapiens Homo sapiens IL6
(interleukine 6; IL-6)], anticorps monoclonal humanisy; 

chaone lourde gamma4 (1-447) [VH humanisy (Homo sapiens IGHV3-72*01
(84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo sapiens IGHG4*01
charniire S10(228)>P (121-447)], (134-214?)-disulfure avec la chaone
lygire kappa (1'-214') [V-KAPPA humanisy (Homo sapiens IGKV1-33*01
(84.20%) -IGKJ2*01) [6.3.9] (1?-107?) -Homo sapiens IGKC*01
(108?-214?)]; dimire (226-226":229-229")-bisdisulfure

inmunoglobulina G4-kappa, anti-[Homo sapiens Homo sapiens IL6
(interleukina 6; IL-6)], anticuerpo monoclonal humanizado;

cadena pesada gamma4 (1-447) [VH humanizado (Homo sapiens IGHV3-72*01
(84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo sapiens IGHG4*01
bisagra S10(228)>P (121-447)], (134-214?)-

disulfuro con la cadena ligera kappa (1?-214?) [V-KAPPA humanizado (Homo
sapiens IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1?-107?) - Homo sapiens
IGKC*01 (108?-214?)]; dnmero (226-226":229-229")-bisdisulfuro

	

WHO 

International Nonproprietary Names Programme	

30/06/2010

9333



		

